[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578808":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":11,"studyPopulation":11,"armGroups":49,"interventions":55,"overallOfficials":60,"centralContacts":64,"locations":73,"responsibleParty":196,"collaborators":11,"id":198,"slug":11,"hasResults":199,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":11,"eligibilityCriteria":203,"healthyVolunteers":199,"sex":204,"minAge":205,"maxAge":11,"enrollmentInfo":206,"targetDuration":11,"studyType":209,"phases":210,"briefSummary":212,"conditions":213,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":225},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Dose-limiting toxicities（DLT）",null,"21 days",{"measure":14,"description":11,"timeFrame":15},"Adverse event (AE)","Up to 2 years",[17,19,21,23,25,27,29,31,33,35,37,39,41],{"measure":18,"description":11,"timeFrame":15},"Cmax",{"measure":20,"description":11,"timeFrame":15},"Tmax",{"measure":22,"description":11,"timeFrame":15},"Area under the Plasma Concentration versus Time Curve (AUC)",{"measure":24,"description":11,"timeFrame":15},"Ctrough",{"measure":26,"description":11,"timeFrame":15},"Objective Response Rate (ORR)",{"measure":28,"description":11,"timeFrame":15},"Disease Control Rate (DCR)",{"measure":30,"description":11,"timeFrame":15},"Overall Survival (OS)",{"measure":32,"description":11,"timeFrame":15},"Progression-Free Survival (PFS)",{"measure":34,"description":11,"timeFrame":15},"Duration of Response (DOR)",{"measure":36,"description":11,"timeFrame":15},"Time to Response (TTR)",{"measure":38,"description":11,"timeFrame":15},"Best Overall Response (BOR)",{"measure":40,"description":11,"timeFrame":15},"Percent change from baseline in the sum of diameters of target lesions",{"measure":42,"description":11,"timeFrame":15},"Best reduction percent change from baseline in the sum of diameters of target lesions",{"allocation":44,"interventionModel":45,"interventionModelDescription":11,"primaryPurpose":46,"observationalModel":11,"timePerspective":11,"maskingInfo":47},"NA","SINGLE_GROUP","TREATMENT",{"masking":48,"maskingDescription":11,"whoMasked":11},"NONE",[50],{"label":51,"type":52,"description":11,"interventionNames":53},"ONO-7428","EXPERIMENTAL",[54],"Drug: ONO-7428",[56],{"type":57,"name":51,"description":58,"armGroupLabels":59,"otherNames":11},"DRUG","Specified dose on specified days",[51],[61],{"name":62,"affiliation":5,"role":63},"Project Leader","STUDY_DIRECTOR",[65,70],{"name":66,"role":67,"phone":68,"phoneExt":11,"email":69},"North America Clinical Trial Support Desk","CONTACT","+18665877745(Toll-Free)","clinical_trial@ono-pharma.com",{"name":71,"role":67,"phone":72,"phoneExt":11,"email":69},"International Clinical Trial Support Desk","+17162141777(Standard)",[74,87,96,105,114,123,131,140,148,157,164,172,181,189,193],{"facility":75,"status":76,"city":77,"state":78,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":86,"contacts":11},"Nagoya University Hospital","RECRUITING","Nagoya","Aichi-ken","Japan","JP",{"type":82,"coordinates":83},"Point",[84,85],136.90641,35.18147,{"lat":85,"lon":84},{"facility":88,"status":76,"city":89,"state":90,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":91,"geoPoint":95,"contacts":11},"National Cancer Center Hospital East","Kashiwa","Chiba",{"type":82,"coordinates":92},[93,94],139.97732,35.86224,{"lat":94,"lon":93},{"facility":97,"status":76,"city":98,"state":99,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":100,"geoPoint":104,"contacts":11},"Kurume University Hospital","Kurume","Fukuoka",{"type":82,"coordinates":101},[102,103],130.51667,33.31667,{"lat":103,"lon":102},{"facility":106,"status":76,"city":107,"state":108,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":109,"geoPoint":113,"contacts":11},"Hyogo Medical University Hospital","Nishinomiya","Hyōgo",{"type":82,"coordinates":110},[111,112],135.33199,34.71562,{"lat":112,"lon":111},{"facility":115,"status":76,"city":116,"state":117,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":118,"geoPoint":122,"contacts":11},"Kitasato University Hospital","Sagamihara","Kanagawa",{"type":82,"coordinates":119},[120,121],139.24167,35.56707,{"lat":121,"lon":120},{"facility":124,"status":76,"city":125,"state":117,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":126,"geoPoint":130,"contacts":11},"Kanagawa Cancer Center","Yokohama",{"type":82,"coordinates":127},[128,129],139.65,35.43333,{"lat":129,"lon":128},{"facility":132,"status":76,"city":133,"state":134,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":135,"geoPoint":139,"contacts":11},"Kochi Medical School Hospital","Nankoku","Kochi",{"type":82,"coordinates":136},[137,138],133.64937,33.56943,{"lat":138,"lon":137},{"facility":141,"status":76,"city":142,"state":142,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":143,"geoPoint":147,"contacts":11},"Kyoto University Hospital","Kyoto",{"type":82,"coordinates":144},[145,146],135.75385,35.02107,{"lat":146,"lon":145},{"facility":149,"status":76,"city":150,"state":151,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":152,"geoPoint":156,"contacts":11},"Kansai Medical University Hospital","Hirakata","Osaka",{"type":82,"coordinates":153},[154,155],135.64914,34.81352,{"lat":155,"lon":154},{"facility":158,"status":76,"city":151,"state":151,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":159,"geoPoint":163,"contacts":11},"Osaka International Cancer Institute",{"type":82,"coordinates":160},[161,162],135.50107,34.69379,{"lat":162,"lon":161},{"facility":165,"status":76,"city":166,"state":151,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":167,"geoPoint":171,"contacts":11},"Kindai University Hospital","Sakai",{"type":82,"coordinates":168},[169,170],135.46653,34.58216,{"lat":170,"lon":169},{"facility":173,"status":76,"city":174,"state":175,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":176,"geoPoint":180,"contacts":11},"Saitama Medical University International Medical Center","Hidaka","Saitama",{"type":82,"coordinates":177},[178,179],139.36233,35.91664,{"lat":179,"lon":178},{"facility":182,"status":76,"city":183,"state":175,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":184,"geoPoint":188,"contacts":11},"Saitama Cancer Center","Shinden",{"type":82,"coordinates":185},[186,187],139.62486,35.99971,{"lat":187,"lon":186},{"facility":190,"status":76,"city":191,"state":192,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital","Bunkyō-Ku","Tokyo",{"facility":194,"status":76,"city":195,"state":192,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"The Cancer Institute Hospital Of JFCR","Koto-Ku",{"type":197,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100578808",false,"NCT06816108","A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors","A Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerability and Safety of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors","Inclusion Criteria:\n\n1. Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors.\n\n   \\[Backfill cohort only\\] Participants with histologically or cytologically confirmed Stage IIIB, IIIC, IV, or recurrent NSCLC according to UICC-TNM classification.\n2. Participants who are refractory or intolerant to standard therapy.\n3. Participants with a tumor type for which anti-PD-(L)1 antibodies have been approved and who have previously treated with anti-PD-(L)1 antibody containing regimen.\n4. Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1.\n5. Participants with tumor tissue samples available for biomarker testing.\n\nExclusion Criteria:\n\n1. Participants with a complication or history of severe hypersensitivity to any other antibody drugs.\n2. Participants with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease\n3. Participants with severe peritoneal dissemination.\n4. Participants with pericardial fluid, pleural effusion, or ascites requiring treatment.\n5. Participants with uncontrolled tumor-related pain.\n6. Participants with active or history of interstitial lung disease or pulmonary fibrosis.","ALL","18 Years",{"count":207,"type":208},60,"ESTIMATED","INTERVENTIONAL",[211],"PHASE1","This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.",[214,215],"Solid Tumor","NSCLC","2026-01-09",{"date":218,"type":219},"2026-01-12","ACTUAL",{"date":221,"type":219},"2025-04-21",{"date":223,"type":208},"2029-07",{"name":5,"class":6},15]